Hydroxychloroquine for Non-Hospitalized COVID-19 Patients: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. [PDF]
Lucchetta R +10 more
europepmc +1 more source
[Could authorization for off-label use be beneficial to the Brazilian Unified National Health System?] [PDF]
Santos MDS +5 more
europepmc +1 more source
Avaliação da resposta aos esquemas de tratamento reduzidos para malária vivax
Recaídas que podem ocorrer com o tratamento convencional de longa duração para malária por P. vivax, são em parte devido a parcial adesão do paciente ao tratamento. A utilização de esquemas terapêuticos de curta duração pode proporcionar melhor adesão ao
Nagib Ponteira Abdon +3 more
doaj
Antimaláricos: construcción de híbridos moleculares de la cloroquina
Antimalarials: construction of molecular hybrids based on chloroquine. The resistance developed by Plasmodium falciparum againsttraditional 4-amino-7-chloroquinolinic drugs has lead to the design and synthesis of dual inhibitors such as chloroquine hybrids.
Kouznetsov, Vladímir V. +1 more
openaire +2 more sources
Daño en el ADN de linfocitos humanos por efecto de cloroquina
El objetivo del estudio fue evaluar el efecto de cloroquina (CQ) en linfocitos humanos a través del ensayo cometa. Los linfocitos fueron aislados de muestras de sangre periférica obtenidas de tres donantes sanos, no fumadores de 24 a 30 años.
Zulita Prieto +2 more
core +1 more source
Se evaluó la frecuencia de mutaciones en los genes pfCRT y DHFR/DHPS del Plasmodium falciparum asociados a la resistencia a cloroquina y sulfadoxina-pirimetamina en 83 cepas provenientes de los distritos Esmeralda y Machala ubicados en las fronteras ...
Nancy Arróspide +6 more
doaj
[Evidence of effectiveness in the pharmacological management of patients with COVID-19]. [PDF]
Pineda Rivera H, Tataje-Lavanda L.
europepmc +1 more source
[Central nervous system adverse events potentially associated with drugs used for COVID-19: scoping reviewEventos adversos en el sistema nervioso central potencialmente relacionados con los medicamentos para tratar la COVID-19: revisión exploratoria]. [PDF]
de Mello V +5 more
europepmc +1 more source
[SARS-CoV-2 infection in patients with sickle cell disease]. [PDF]
Argüello-Marina M +2 more
europepmc +1 more source

